Add like
Add dislike
Add to saved papers

Relationships between type 1 IFN signatures and clinical features of the newly-onset lupus patients in Japan.

Modern Rheumatology 2023 January 26
OBJECTIVES: To investigate the relationships between type 1 interferon (T1-IFN) signatures and clinical characteristic in lupus patients.

METHODS: We examined 49 patients with newly-onset patients, who were diagnosed between 1999 and 2017. The patients treated with more than 10 mg of prednisolone or hydroxychloroquine were excluded from this study. Serum T1-IFN signatures were revealed by a functional reporter assay, and standardized by recombinant IFN-α. Patient backgrounds, clinical findings and treatments were retrospectively extracted from their electrical medical records. Clinical data were also available, including SLE Disease Activity Index (SLEDAI) of SLE patients on admission.

RESULTS: Type 1 IFN signatures of lupus patients closely correlated with lupus disease activity, such as SLEDAI-2K, WBC, C3 levels and the titer of ds-DNA antibody. We found fever and acute lupus dermatitis closely associated with T1-IFN signature.

CONCLUSIONS: In lupus patients, fever and acute lupus dermatitis are good indicators of a strong type 1 IFN signature.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app